Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
The protein encoded by BTG3 is a member of the BTG/Tob family. Zusätzlich bieten wir Ihnen BTG3 Kits (15) und BTG3 Proteine (5) und viele weitere Produktgruppen zu diesem Protein an.
Showing 10 out of 43 products:
Human Polyclonal BTG3 Primary Antibody für ICC, IF - ABIN4285522
Deng, Zhao, Gou, Chen, Mao, Takano, Zheng: Decreased expression of BTG3 was linked to carcinogenesis, aggressiveness, and prognosis of ovarian carcinoma. in Tumour biology 2013
Deficiency of antiproliferative family protein Ana correlates with development of lung adenocarcinoma.
Results suggest that ANA is a suppressor of ectopic bone formation induced by bone morphogenetic proteins, and this inhibitory ANA activity is a part of the negative feedback regulation of BMP function.
Data show that miR-139 can repress the proliferation of hepatocellular carcinoma (HCC) cells via directly inhibiting the expression of ANA protein, human Add B-cell translocation gene 3 protein (BTG3).
Taken together, the results of our study suggest that BTG3 overexpression could inhibit cell proliferation and invasion and promotes cell apoptosis in EOC cell, possibly by regulating the AKT/GSK3beta/beta-catenin signaling pathway
BTG3 expression might contribute to CRC carcinogenesis. BTG3 knockdown might strengthen the aggressive colorectal cancer behavior.
BTG3 is a direct downstream target of miR-106b-5p.
BTG3 overexpression inhibited tumor growth of SW620 cells by suppressing proliferation and inducing apoptosis. It was suggested that down-regulated BTG3 expression might be considered as a marker for colorectal carcinogenesis.
ANA and ASMA evaluation in patients with liver transplantation and no history of autoimmune disease has no clinical relevance, since it varies in time and is not related to any risk factors or liver injury. Routine autoimmunity evaluation should be avoided.
BTG3 overexpression might reverse the aggressive phenotypes and be employed as a potential target for gene therapy of gastric cancer.
The suppressed migration and invasion abilities found in BTG3-overexpressing esophageal adenocarcinoma cells. Our findings suggested that BTG3 is suppressor in the progression of esophageal adenocarcinoma
BTG3 binds and suppresses AKT, a kinase frequently deregulated in cancers.
Down-regulation of BTG3 promotes cell proliferation, migration and invasion in gastric cancer.
BTG3 protein expression may be considered as a good marker to indicate the favorable prognosis of epithelial ovarian carcinoma.
These results disclosed an important role of BTG3 in lung tumorigenesis.
BTG3-dependent CHK1 ubiquitination contributes to its chromatin localization and activation and a defect in this regulation may increase genome instability and promote tumorigenesis
loss of BTG3 in normal cells induced cellular senescence, which was correlated with enhanced ERK-AP1 signaling and elevated expression of the histone H3K27me3 demethylase JMJD3/KDM6B
by disrupting the DNA binding activity of E2F1, BTG3 participates in the regulation of E2F1 target gene expression. Therefore, our studies have revealed a previously unidentified pathway through which the activity of E2F1 may be guarded by activated p53.
These data support the hypothesis that BTG3 may act to suppress tumorigenesis and that hypermethylation is an important mechanism for inactivation of BTG3 and perhaps other tumor suppressor genes.
BTG3 is epigenetically silenced in renal cancer
The protein encoded by this gene is a member of the BTG/Tob family. This family has structurally related proteins that appear to have antiproliferative properties. This encoded protein might play a role in neurogenesis in the central nervous system. Two transcript variants encoding different isoforms have been found for this gene.
B cell translocation protein 3
, protein BTG3
, B-cell translocation gene 3
, BTG family member 3
, abundant in neuroepithelium area protein
, protein Tob5